Fort Lee, New Jersey, USA, April 16, 2015 (GLOBE NEWSWIRE) -- Herborium® Group, Inc. (OTC Pink: HBRM), www.Herborium.com, a Botanical Therapeutics® Company providing unique, all botanical medicines (Botanical Therapeutics®), announced today its 2015 First Quarter financial results. The company filed the Quarterly Financial Report with OTC, on Wednesday April 15th, 2015.
The Company results for the First Quarter of 2015 confirm continuing and rapid growth and mark the ninth consecutive quarter of double digit sales growth.
The company achieved an overall growth in revenues and gross profit while maintaining a very advantageous gross margin. In the First Quarter of 2015 the Company also further decreased loss from operations, increased both e-commerce and wholesale orders, and improved it's brand recognition. All of the above factors represent pivotal drivers in Herborium's prospects for continuous and successful growth in 2015.
· Herborium sales increased over 21% in comparison to the same quarter of 2014.
· The sales increase resulted from both: an increase in e- commerce and wholesale orders
· While increasing revenues the Company maintained gross margin of over 64%
· Gross Profit increased over 23%
· Company's operating expenses remained constant in comparison to the First Quarter of 2014
· The overall net loss decreased by 25% over the same period of 2014
Herborium remains very optimistic about growing its business, sales and product awareness due to the steady growth of the AcnEase® brand in the US and abroad as well as a number of new products scheduled to enter the market in 2015. .The Company continues its efforts to increase market penetration in both retail and wholesale sectors and to decrease costs and retire debt. We expect the growth and profitability of our novel, all natural medicines - Botanical Therapeutics®" to continue in 2015 ", commented Dr. Agnes P. Olszewski, CEO and Chairwoman of Herborium Group.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company that develops, license and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women's health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, diabetes, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, www.acnease.com, www.acnease.fr and www.herboriumsh.com.
Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.